These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17438713)

  • 21. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
    Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X
    Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Examination of somatostatin receptor expression in recurrent childhood medulloblastomas].
    Kaszper E; Hanzély Z; Szende B; Dabasi G; Garami M; Schuler D; Hauser P
    Magy Onkol; 2008 Dec; 52(4):351-5. PubMed ID: 19068462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma.
    Klutmann S; Bohuslavizki KH; Tietje N; Kröger S; Behnke A; Brenner W; Mester J; Henze E; Clausen M
    J Nucl Med; 1999 Aug; 40(8):1246-51. PubMed ID: 10450673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
    Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
    Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
    Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
    Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
    Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.
    Dromain C; de Baere T; Lumbroso J; Caillet H; Laplanche A; Boige V; Ducreux M; Duvillard P; Elias D; Schlumberger M; Sigal R; Baudin E
    J Clin Oncol; 2005 Jan; 23(1):70-8. PubMed ID: 15625361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study.
    Dörr U; Würstlin S; Frank-Raue K; Raue F; Hehrmann R; Iser G; Scholz M; Guhl L; Buhr HJ; Bihl H
    Horm Metab Res Suppl; 1993; 27():48-55. PubMed ID: 8330872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
    Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
    J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor?
    Kropp J; Hofmann M; Bihl H
    Anticancer Res; 1997; 17(3B):1583-8. PubMed ID: 9179198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Imaging of somatostatin receptor using 111In-pentetreotide].
    Kimura T; Sakahara H; Higashi T; Honda T; Konishi J; Hosotani R; Oshio G; Imamura M; Inokuma T
    Kaku Igaku; 1996 Apr; 33(4):447-52. PubMed ID: 8683886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor.
    Fouladi M; Gajjar A; Boyett JM; Walter AW; Thompson SJ; Merchant TE; Jenkins JJ; Langston JW; Liu A; Kun LE; Heideman RL
    J Clin Oncol; 1999 Oct; 17(10):3234-7. PubMed ID: 10506624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic indium-111-pentetreotide scintigraphy in breast cancer.
    Bajc M; Ingvar C; Palmer J
    J Nucl Med; 1996 Apr; 37(4):622-6. PubMed ID: 8691252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors.
    Schillaci O; Scopinaro F; Angeletti S; Tavolaro R; Danieli R; Annibale B; Gualdi G; Delle Fave G
    J Nucl Med; 1996 Sep; 37(9):1452-6. PubMed ID: 8790191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indium-111-pentetreotide in Graves' disease.
    Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
    J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
    Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC.
    Freudenberg LS; Gauler T; Görges R; Bauer S; Stergar H; Antoch G; Bockisch A; Schütte J
    Nuklearmedizin; 2008; 47(3):127-31. PubMed ID: 18493693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
    Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
    Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
    Savelli G; Lucignani G; Seregni E; Marchianò A; Serafini G; Aliberti G; Villano C; Maccauro M; Bombardieri E
    Nucl Med Commun; 2004 May; 25(5):445-9. PubMed ID: 15100502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.